ClinicalTrials.gg
CompletedNCT01594125Updated Feb 12, 2016Results posted

Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma

A Phase 1 interventional study of Nintedanib high dose and Nintedanib low dose in Carcinoma, Hepatocellular, sponsored by Boehringer Ingelheim. Completed at 5 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2016-02-12.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 115 studies in Carcinoma, Hepatocellular with a site in Japan — 17 open to participants now, 32 under way, 9 of them phase 3. Carcinoma, Hepatocellular · Japan.

Enrollment
86th of 103
30 · median 182
Started
2012
with 4 others
Phase 1
29 of 115
5 open now
Registered
33rd of 115
by date

Among the 115 studies in Carcinoma, Hepatocellular with a site in Japan, this one is the 86th largest by enrollment of the 103 interventional ones that give a count, is one of 5 that started in 2012, is one of 29 in phase 1, and was the 33rd registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

17 of the 115 studies in Carcinoma, Hepatocellular with a site in Japan are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Carcinoma, Hepatocellular with a site in Japan, or all of them as a file.
02

Study summary

The aim of the study is to investigate the safety, tolerability, efficacy and pharmacokinetics (PK) for Japanese hepatocellular carcinoma which are not amenable to curative surgery or loco regional therapy

03

Conditions studied

  • Carcinoma, Hepatocellular
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histologically/ confirmed hepatocellular carcinoma not amenable to curative surgery or loco-regional therapy
  2. Age 20 years or older
  3. (ECOG) performance status (PS) score of 0 or 1
  4. score of 7 or less
  5. more than 3 months
  6. Time interval from last loco-regional therapy more than 4 weeks
  7. Written in accordance with good clinical practice (GCP)

Exclusion criteria

Exclusion criteria:

  1. More than one line of prior systemic therapy for /unresectable hepatocellular carcinoma (HCC)
  2. Fibrolamellar HCC
  3. Uncontrolled or ascites
  4. Inadequate organ function
  5. Variceal bleeding within 6 months or the presence of inappropriate varices
  6. History of major thrombotic (except portal vein thrombosis) or major bleeding event in the past 6 months
  7. Major surgery within 4 weeks
  8. Known inherited predisposition to bleeding or thrombosis
  9. Significant cardiovascular diseases
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Group I

    patients with mild liver dysfunction according to their AST/ALT values and Child-Pugh score

    Drug: Nintedanib high dose · Drug: Nintedanib medium dose

  • Experimental
    Group II

    patients with moderate liver dysfunction according to their AST/ALT values and Child-Pugh score

    Drug: Nintedanib low dose · Drug: Nintedanib medium dose · Drug: Nintedanib high dose

Interventions

  • DrugNintedanib high dose

    twice daily oral dosing

  • DrugNintedanib low dose

    twice daily oral dosing

  • DrugNintedanib medium dose

    twice daily oral dosing

  • DrugNintedanib medium dose

    twice daily oral dosing

  • DrugNintedanib high dose

    twice daily oral dosing

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Nintedanib

    The MTD is based on the incidence of Dose Limiting Toxicities (DLTs). A drug-related AE was considered as a DLT if one of the following met: CTCAE grade 4 thrombocytopenia of any duration, CTCAE grade 4 neutropenia lasting for ≥8 days, CTCAE grade 4 febrile neutropenia of any duration, CTCAE grade 3 or 4 non-haematologic toxicity (with the following exception: Alopecia, Vomiting, nausea, or diarrhoea with no adequate supportive care, Transient electrolyte abnormality, which resolves spontaneously or can be corrected with appropriate treatment within 3 days, Liver toxicity), Liver enzyme toxicity of AST, ALT, alkaline phosphatase \[ALP\] elevation \>5x ULN, or total bilirubin \>3x ULN if baseline liver enzymes are within the normal range, or AST, ALT or ALP \> baseline value + 4x ULN if the baseline value is elevated. The MTD was determined to be 200mg bid.

    Time frame: up to 28 days

Secondary outcomes

  1. Number of Participants With Objective Tumour Response According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0

    Objective response (Complete response (CR) + Partial response (PR), regardless of confirmation) is derived from a patient's best objective response by RECIST. Best objective response is calculated based on the "overall" visit response from each assessment. Best objective response represents the best response a patient has had during their time in the study up until progression, last evaluable assessment in the absence of progression or the start of subsequent anti-cancer therapy. For patients whose progression event is death, best objective response will be calculated based on data up until the last evaluable RECIST assessment prior to death.

    Time frame: up to 28 months

  2. Progression Free Survival (PFS)

    PFS is defined as the duration from start date of the study treatment to PD according to RECIST 1.0, or any death whichever occurs earlier.

    Time frame: up to 28 months

  3. Time to Progression (TTP)

    TTP is defined as the duration from the start date of the study treatment to PD according to RECIST 1.0.

    Time frame: up to 28 months

  4. Number of Participants With Response by Alpha Fetoprotein (AFP)

    Response by AFP is defined as 20% or more decline in AFP between the baseline value and the AFP value after three courses (12 weeks) of therapy. If patients only receive two courses of therapy the AFP value after two courses (8 weeks) will be used for the analysis.

    Time frame: up to 28 months

07

Results

Posted Dec 22, 2015

Participant flow

Participant flow — Overall Study
MilestoneGroup I: Nintedanib 150mg BidGroup I: Nintedanib 200mg BidGroup II: Nintedanib 100mg BidGroup II: Nintedanib 150mg BidGroup II: Nintedanib 200mg Bid
Started412347
Completed00000
Not completed412347
Withdrew: Withdrawal by subject10010
Withdrew: Progressive disease312337

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Nintedanib

The MTD is based on the incidence of Dose Limiting Toxicities (DLTs). A drug-related AE was considered as a DLT if one of the following met: CTCAE grade 4 thrombocytopenia of any duration, CTCAE grade 4 neutropenia lasting for ≥8 days, CTCAE grade 4 febrile neutropenia of any duration, CTCAE grade 3 or 4 non-haematologic toxicity (with the following exception: Alopecia, Vomiting, nausea, or diarrhoea with no adequate supportive care, Transient electrolyte abnormality, which resolves spontaneously or can be corrected with appropriate treatment within 3 days, Liver toxicity), Liver enzyme toxicity of AST, ALT, alkaline phosphatase \[ALP\] elevation \>5x ULN, or total bilirubin \>3x ULN if baseline liver enzymes are within the normal range, or AST, ALT or ALP \> baseline value + 4x ULN if the baseline value is elevated. The MTD was determined to be 200mg bid.

Time frame:
up to 28 days
Reported as:
Number · participants
Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Nintedanib
participantsGroup I: Nintedanib 150mg BidGroup I: Nintedanib 200mg BidGroup II: Nintedanib 100mg BidGroup II: Nintedanib 150mg BidGroup II: Nintedanib 200mg Bid
Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Nintedanib00000
SecondaryNumber of Participants With Objective Tumour Response According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0

Objective response (Complete response (CR) + Partial response (PR), regardless of confirmation) is derived from a patient's best objective response by RECIST. Best objective response is calculated based on the "overall" visit response from each assessment. Best objective response represents the best response a patient has had during their time in the study up until progression, last evaluable assessment in the absence of progression or the start of subsequent anti-cancer therapy. For patients whose progression event is death, best objective response will be calculated based on data up until the last evaluable RECIST assessment prior to death.

Time frame:
up to 28 months
Reported as:
Number · participants
Number of Participants With Objective Tumour Response According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0
participantsGroup I: Nintedanib 150mg BidGroup I: Nintedanib 200mg BidGroup II: Nintedanib 100mg BidGroup II: Nintedanib 150mg BidGroup II: Nintedanib 200mg Bid
Number of Participants With Objective Tumour Response According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.000000
SecondaryProgression Free Survival (PFS)

PFS is defined as the duration from start date of the study treatment to PD according to RECIST 1.0, or any death whichever occurs earlier.

Time frame:
up to 28 months
Reported as:
Median · months
Progression Free Survival (PFS)
monthsGroup I: Nintedanib 150mg BidGroup I: Nintedanib 200mg BidGroup II: Nintedanib 100mg BidGroup II: Nintedanib 150mg BidGroup II: Nintedanib 200mg Bid
Progression Free Survival (PFS)6.05 (0.95 to 8.25)2.76 (1.74 to 5.42)7.26 (3.68 to 7.39)2.40 (1.48 to 6.88)2.76 (0.95 to 5.62)
SecondaryTime to Progression (TTP)

TTP is defined as the duration from the start date of the study treatment to PD according to RECIST 1.0.

Time frame:
up to 28 months
Reported as:
Median · months
Time to Progression (TTP)
monthsGroup I: Nintedanib 150mg BidGroup I: Nintedanib 200mg BidGroup II: Nintedanib 100mg BidGroup II: Nintedanib 150mg BidGroup II: Nintedanib 200mg Bid
Time to Progression (TTP)6.05 (0.95 to 8.25)2.76 (1.74 to 5.42)7.26 (3.68 to 7.39)2.40 (1.48 to 6.88)2.76 (0.95 to 5.62)
SecondaryNumber of Participants With Response by Alpha Fetoprotein (AFP)

Response by AFP is defined as 20% or more decline in AFP between the baseline value and the AFP value after three courses (12 weeks) of therapy. If patients only receive two courses of therapy the AFP value after two courses (8 weeks) will be used for the analysis.

Time frame:
up to 28 months
Reported as:
Number · participants
Number of Participants With Response by Alpha Fetoprotein (AFP)
participantsGroup I: Nintedanib 150mg BidGroup I: Nintedanib 200mg BidGroup II: Nintedanib 100mg BidGroup II: Nintedanib 150mg BidGroup II: Nintedanib 200mg Bid
Number of Participants With Response by Alpha Fetoprotein (AFP)21111

Adverse events

Collected over up to 67 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group I: Nintedanib 150mg Bid—0/4 (0%)4/4 (100%)
Group I: Nintedanib 200mg Bid—4/12 (33.3%)12/12 (100%)
Group II: Nintedanib 100mg Bid—1/3 (33.3%)3/3 (100%)
Group II: Nintedanib 150mg Bid—2/4 (50%)4/4 (100%)
Group II: Nintedanib 200mg Bid—3/7 (42.9%)7/7 (100%)
Most frequent serious events
Most frequent serious events
EventGroup I: Nintedanib 150mg BidGroup I: Nintedanib 200mg BidGroup II: Nintedanib 100mg BidGroup II: Nintedanib 150mg BidGroup II: Nintedanib 200mg Bid
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/41/121/32/41/7
GastroenteritisInfections and infestations0/40/121/30/40/7
AscitesGastrointestinal disorders0/40/120/31/40/7
PyrexiaGeneral disorders0/40/120/30/41/7
Drug-induced liver injuryHepatobiliary disorders0/40/120/30/41/7
Tumour embolismNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/40/120/30/41/7
Immune thrombocytopenic purpuraBlood and lymphatic system disorders0/41/120/30/40/7
Abdominal painGastrointestinal disorders0/41/120/30/40/7
HyponatraemiaMetabolism and nutrition disorders0/41/120/30/40/7
Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/41/120/30/40/7
Most frequent other events
Showing 10 of 103
Most frequent other events
EventGroup I: Nintedanib 150mg BidGroup I: Nintedanib 200mg BidGroup II: Nintedanib 100mg BidGroup II: Nintedanib 150mg BidGroup II: Nintedanib 200mg Bid
NauseaGastrointestinal disorders0/47/120/34/41/7
Decreased appetiteMetabolism and nutrition disorders2/44/121/34/42/7
VomitingGastrointestinal disorders0/46/120/33/40/7
FatigueGeneral disorders2/41/122/33/40/7
Blood bilirubin increasedInvestigations0/41/121/33/40/7
LeukopeniaBlood and lymphatic system disorders0/40/122/30/41/7
NeutropeniaBlood and lymphatic system disorders2/40/122/31/40/7
Alanine aminotransferase increasedInvestigations1/40/122/31/41/7
Aspartate aminotransferase increasedInvestigations1/43/122/32/41/7
HypoalbuminaemiaMetabolism and nutrition disorders0/42/122/32/42/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group I: Nintedanib 150mg BidGroup I: Nintedanib 200mg BidGroup II: Nintedanib 100mg BidGroup II: Nintedanib 150mg BidGroup II: Nintedanib 200mg BidTotal
Mean67.0 ± 14.7263.1 ± 9.8473.3 ± 2.3166.5 ± 6.5667.4 ± 4.3566.1 ± 8.81
Sex: Female, Male
Sex: Female, Male(Participants)Group I: Nintedanib 150mg BidGroup I: Nintedanib 200mg BidGroup II: Nintedanib 100mg BidGroup II: Nintedanib 150mg BidGroup II: Nintedanib 200mg BidTotal
Female213219
Male21102621
08

Study locations

5 sites
  • 1199.120.001 Boehringer Ingelheim Investigational Site
    Chuo-ku, Tokyo, Japan
  • 1199.120.005 Boehringer Ingelheim Investigational Site
    Fukuoka, Fukuoka, Japan
  • 1199.120.002 Boehringer Ingelheim Investigational Site
    Kashiwa, Chiba, Japan
  • 1199.120.003 Boehringer Ingelheim Investigational Site
    Nagoya, Aichi, Japan
  • 1199.120.004 Boehringer Ingelheim Investigational Site
    Saga, Saga, Japan
09

References and documents

Publications

  • Okusaka T, Otsuka T, Ueno H, Mitsunaga S, Sugimoto R, Muro K, Saito I, Tadayasu Y, Inoue K, Loembe AB, Ikeda M. Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment. Cancer Sci. 2016 Dec;107(12):1791-1799. doi: 10.1111/cas.13077. Epub 2016 Dec 12. PubMed 27627050 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Nov 2014 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2012
First posted
May 8, 2012
Start
May 2012
Primary completionActual
Nov 2014
CompletionActual
Jan 2015
Results first posted
Dec 22, 2015
Last update
Feb 12, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01594125
Responsible party
Sponsor
First posted
May 8, 2012
Start date
May 2012
Primary completion
Nov 2014
Completion
Jan 2015
Results posted
Dec 22, 2015
Last update
Feb 12, 2016

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion